Spoken Alpha
Neurogene Inc.
Neurogene develops genetic medicines for severe neurological diseases using its proprietary EXACT transgene regulation technology. The company's lead program, NGN-401, is in Phase 3 clinical development for Rett syndrome, a rare neurodevelopmental disorder affecting approximately 15,000-20,000 patients in major markets.
Neurogene Inc is a Healthcare company operating in Biotechnology with a $642.2M market cap.
NGNE missed consensus EPS by 0.1% in Q2 FY2026, reported Aug 10, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add NGNE, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NGNE.
$ curl https://api.spokenalpha.com/v1/companies/NGNEFAQ
Spoken Alpha indexes NGNE's earnings call transcripts at https://spokenalpha.com/companies/NGNE. Each call links to attributed speakers and parsed analyst Q&A. Neurogene Inc.'s own investor relations page is at https://ir.neurogene.com/.
Neurogene Inc. (NGNE) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | $-1.53 | $-1.40 | -9.3% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-1.39 | $-1.27 | -9.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $-1.13 | $-1.24 | +8.9% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.99 | $-1.09 | +9.2% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-1.05 | $-1.16 | +9.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-1.08 | $-1.12 | +3.6% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-23 | $-0.99 | $-1.13 | +12.4% | $-925.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-17 | $-1.19 | $-1.22 | +2.5% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-1.09 | $-1.03 | -5.8% | $925.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $-1.00 | $-0.95 | -5.3% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-17 | $-1.51 | $-1.17 | -29.1% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.41 | $-0.03 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-15 | $-0.04 | $-0.04 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.26 | $-0.22 | -18.2% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-15 | $-0.24 | $-0.19 | -26.3% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.24 | $-0.30 | +21.1% | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.28 | $-0.30 | +6.7% | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.28 | $-0.30 | +6.0% | — | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $-0.28 | $-0.30 | +5.3% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.28 | $-0.28 | -0.6% | — | — | — | EODHD |
Source: EODHD. NGNE reported actuals as published; sparse fields render as —.